-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Kinetix Group and Pfizer Health Equity Work Recognized by PM360
The Kinetix Group and Pfizer Health Equity Work Recognized by PM360
NEW YORK, March 29, 2024 /PRNewswire/ -- The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones.
The Pfizer Inflammation and Immunology Strategic Customer Group originally developed the idea to address a gap in equitable patient and provider education resources surrounding atopic dermatitis. The team partnered with TKG to drive awareness for patients with skin of color.
"I am proud to be a part of a company like TKG, where there is a genuine commitment to addressing health equity and social determinants of health. TKG not only cares about these issues but actively collaborates with others in the industry who share the same dedication to making a difference for patients. Being recognized for my contribution is a significant accomplishment, and it is encouraging to see a growing awareness and concern for these critical issues," said Haley Toomer, manager and member of the winning team.
As an industry-voted award, the Pharma Choice Awards celebrate the greatest healthcare and life science creatives, chosen by those who know the industry best. Viewers can vote for their favorite entries in 14 categories including Direct-To-Consumer/Direct-To-Patient, Multichannel, Multicultural, Unbranded and more.
"At TKG, we wake up every day driven to find novel ways to speed patient access to lifesaving medication," said Sarah McNulty, president of TKG. "Our business charter involves meeting patients where they are to holistically address their needs. This PM360 award is particularly meaningful because it celebrates the inclusive work that we partner with clients to deliver and our company culture, which values diversity and inclusivity."
For more information about the award, visit here or contact [email protected].
The Kinetix Group (TKG)
The Kinetix Group, a healthcare strategic advisory and marketing agency, is a part of Petauri. TKG empowers life science companies to effectively engage with health system and payer customers. With market access expertise, deep relationships, and connections that span the healthcare ecosystem, TKG is uniquely positioned to understand its clients' customers and design impactful solutions. Its core areas of focus are organized customers, market access, and real-world evidence. To learn more, visit .
SOURCE The Kinetix Group
NEW YORK, March 29, 2024 /PRNewswire/ -- The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones.
纽约,2024年3月29日 /PRNewswire/ — Kinetix集团(TKG)和辉瑞炎症与免疫学因其最近的健康公平计划获得了 PM360 制药选择奖。该奖项认可了辉瑞针对不同肤色的特应性皮炎互动指南。
The Pfizer Inflammation and Immunology Strategic Customer Group originally developed the idea to address a gap in equitable patient and provider education resources surrounding atopic dermatitis. The team partnered with TKG to drive awareness for patients with skin of color.
辉瑞炎症和免疫学战略客户小组最初提出这个想法是为了解决围绕特应性皮炎的公平患者和提供者教育资源方面的差距。该团队与TKG合作,提高了有色肤色患者的认识。
"I am proud to be a part of a company like TKG, where there is a genuine commitment to addressing health equity and social determinants of health. TKG not only cares about these issues but actively collaborates with others in the industry who share the same dedication to making a difference for patients. Being recognized for my contribution is a significant accomplishment, and it is encouraging to see a growing awareness and concern for these critical issues," said Haley Toomer, manager and member of the winning team.
“我很自豪能加入像TKG这样的公司,该公司真诚地致力于解决健康公平和健康的社会决定因素。TKG不仅关心这些问题,而且积极与业内其他有着同样致力于为患者带来改变的奉献精神的人合作。我的贡献获得认可是一项重大成就,看到人们对这些关键问题的认识和关注日益增强,令人鼓舞。” 获胜团队经理兼成员海利·图默说。
As an industry-voted award, the Pharma Choice Awards celebrate the greatest healthcare and life science creatives, chosen by those who know the industry best. Viewers can vote for their favorite entries in 14 categories including Direct-To-Consumer/Direct-To-Patient, Multichannel, Multicultural, Unbranded and more.
作为行业投票的奖项,Pharma Choice Awards旨在表彰由最了解行业的人选出的最伟大的医疗保健和生命科学创作者。观众可以在14个类别中投票选出自己喜欢的参赛作品,包括直接面向消费者/直接面向患者、多渠道、多元文化、无品牌等。
"At TKG, we wake up every day driven to find novel ways to speed patient access to lifesaving medication," said Sarah McNulty, president of TKG. "Our business charter involves meeting patients where they are to holistically address their needs. This PM360 award is particularly meaningful because it celebrates the inclusive work that we partner with clients to deliver and our company culture, which values diversity and inclusivity."
他说:“在TKG,我们每天醒来都在努力寻找新方法来加快患者获得救生药物的速度。” 莎拉·麦克纳尔蒂,TKG 总裁。“我们的商业章程包括在患者所在的地方与他们会面,以全面满足他们的需求。这个 PM360 奖项特别有意义,因为它旨在表彰我们与客户合作交付的包容性工作,以及我们重视多元化和包容性的公司文化。”
For more information about the award, visit here or contact [email protected].
有关该奖项的更多信息,请访问此处或联系 [email protected]。
The Kinetix Group (TKG)
Kinetix 集团 (TKG)
The Kinetix Group, a healthcare strategic advisory and marketing agency, is a part of Petauri. TKG empowers life science companies to effectively engage with health system and payer customers. With market access expertise, deep relationships, and connections that span the healthcare ecosystem, TKG is uniquely positioned to understand its clients' customers and design impactful solutions. Its core areas of focus are organized customers, market access, and real-world evidence. To learn more, visit .
医疗保健战略咨询和营销机构Kinetix集团是Petauri的一部分。TKG使生命科学公司能够有效地与卫生系统和付款人客户互动。凭借市场准入专业知识、深厚的关系和跨越医疗保健生态系统的联系,TKG在了解客户客户和设计有影响力的解决方案方面处于独特的地位。其核心关注领域是有组织的客户、市场准入和真实证据。要了解更多信息,请访问。
SOURCE The Kinetix Group
来源 Kinetix 集团
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧